Prognostic significance of hyperuricemia in patients with different types of renal dysfunction and acute myocardial infarction treated with percutaneous coronary intervention

Nephron - Clinical Practice

Volumn 116, Issue 2, 2010, Pages

  Kowalczyk, Jacek ^a   Francuz, Pawel ^a   Swoboda, Ryszard ^a   Lenarczyk, Radoslaw ^a   Sredniawa, Beata ^a   Golda, Adam ^a   Kurek, Tomasz ^a   Mazurek, Michal ^a   Podolecki, Tomasz ^a   Polonski, Lech ^a   Kalarus, Zbigniew ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Acute myocardial infarction; Contrast induced nephropathy; Hyperuricemia; Kidney dysfunction; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; STATIN; URIC ACID;

ACUTE HEART INFARCTION; ARTICLE; CONTRAST INDUCED NEPHROPATHY; CONTROLLED STUDY; HUMAN; HYPERURICEMIA; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; URIC ACID BLOOD LEVEL;

AGED; ANGIOPLASTY, BALLOON, CORONARY; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HOSPITAL MORTALITY; HUMANS; HYPERURICEMIA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; PROSPECTIVE STUDIES; REGISTRIES; RENAL INSUFFICIENCY; TREATMENT OUTCOME;

EID: 77952478867     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000314660     Document Type: Article

References (47)

1. van Domburg RT, Hoeks SE, Welten GM, Chonchol M, Elhendy A, Poldermans D: Re-nal insufficiency and mortality in patients with known or suspected coronary artery disease. J Am Soc Nephrol 2008; 19: 158-163.
2. Masoudi FA, Plomondon ME, Magid DJ, Sales A, Rumsfeld JS: Renal insufficiency and mortality from acute coronary syn-dromes. Am Heart J 2004; 147: 623-629.
3. Mahon NG, Blackstone EH, Francis GS, Starling RC 3rd, Young JB, Lauer MS: The prognostic value of estimated creatinine clearance alongside functional capacity in ambulatory patients with chronic congestive heart failure. J Am Coll Cardiol 2002; 40: 1106-1113.
4. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Mi-chelson EL, Ostergren J, Cornel JH, de Zeeuw D, Pocock S, van Veldhuisen DJ, Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Investigators: Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 2006; 113:671-678.
5. Sadeghi HM, Stone GW, Grines CL, Mehran R Dixon SR, Lansky AJ, Fahy M, Cox DA, Garcia E, Tcheng JE, Griffin JJ, Stuckey TD, Turco M, Carroll JD: Impact of renal insuf-ficiency in patients undergoing primary an-gioplasty for acute myocardial infarction. Circulation 2003; 108:2769-2775.
6. Kowalczyk J, Lenarczyk R, Kowalski O, Sred-niawa B, Musialik-Lydka A, Gasior M, Po-lonski L, Zembala M, Gumprecht J, Kalarus Z: Different types of renal dysfunction in pa-tients with acute myocardial infarction treated with percutaneous coronary inter-vention. J Interv Cardiol 2007; 20:143-152. (Pubitemid 46457446)
7. Dunkelgrun M, Welten GM, Goei D, Winkel TA, Schouten O, van Domburg RT, van Gestel YR, Flu WJ, Hoeks SE, Bax JJ, Poldermans D: Association between serum uric acid and peri-operative and late cardiovascular outcome in patients with suspected or definite coronary artery disease undergoing elective vascular surgery Am J Cardiol 2008; 102: 797-801.
8. Jankowska EA, Ponikowska B, Majda J, Zymlinski R, Trzaska M, Reczuch K, Boro-dulin-Nadzieja L, Banasiak W, Ponikowski P: Hyperuricemia predicts poor outcome in patients with mild to moderate chronic heart failure. Int J Cardiol 2007; 115:151-155.
9. Madero M, Sarnak MJ, Wang X, Greene T, Beck GJ, Kusek JW, Collins AJ, Levey AS, Menon V: Uric acid and long-term outcomes in CKD. Am J Kidney Dis 2009; 53: 796-803.
10. Suliman ME, Johnson RJ, García-López E, Qureshi AR, Molinaei H, Carrero JJ, Heim-bürger O, Bárány P, Axelsson J, Lindholm B, Stenvinkel P: J-shaped mortality relation-ship for uric acid in CKD. Am J Kidney Dis 2006; 48:761-771.
11. Hsu SP, Pai MF, Peng YS, Chiang CK, Ho TI, Hung KY: Serum uric acid levels show a 'J-shaped' association with all-cause mortality in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 457-462.
12. Kojima S, Sakamoto T, Ishihara M, Kimura K, Miyazaki S, Yamagishi M, Tei C, Hiraoka H, Sonoda M, Tsuchihashi K, Shimoyama N, Honda T, Ogata Y, Matsui K, Ogawa H, Japanese Acute Coronary Syndrome Study (JACSS) Investigators: Prognostic useful-ness of serum uric acid after acute myocar-dial infarction (the Japanese Acute Coro-nary Syndrome Study). Am J Cardiol 2005; 96: 489-495.
13. Lazzeri C, Valente S, Chiostri M, Sori A, Ber-nardo P, Gensini GF: Uric acid in the acute phase of ST elevation myocardial infarction submitted to primary PCI: Its prognostic role and relation with inflammatory mark-ers: a single center experience. Int J Cardiol 2010; 138: 206-209.
14. National Kidney Foundation: K/DOQI clin-ical practice guidelines for chronic kidney disease: evaluation, classification, and strati-fication. Am J Kidney Dis 2002; 39:S1-S266.
15. McCullough PA, Adam A, Becker CR, Da-vidson C, Lameire N, Stacul F, Tumlin J, CIN Consensus Working Panel: Epidemiology and Prognostic Implications of Contrast-In-duced Nephropathy. Am J Cardiol 2006; 98: 5K-13K.
16. Chen JH, Chuang SY, Chen HJ, Yeh WT, Pan WH: Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study. Arthritis Rheum 2009; 61:225-232.
17. Bertrand ME, Simoons ML, Fox KA, Wal-lentin LC, Hamm CW, McFadden E, De Feyter PJ, Specchia G, Ruzyllo W, Task Force on the Management of Acute Coronary Syn-dromes of the European Society of Cardiol-ogy: Management of acute coronary syn-dromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2002; 23: 1809-1840.
18. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ, Schaeffer JW, Smith EE 3rd, Steward DE, Theroux P, Gibbons RJ, Alpert JS, Faxon DP, Fuster V, Gregoratos G, Hiratzka LF, Jacobs AK, Smith SC Jr, American Col-lege of Cardiology, American Heart Associa-tion. Committee on the Management of Pa-tients With Unstable Angina: ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart As-sociation task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002; 40:1366-1374.
19. Van de Werf F, Ardissino D, Betriu A, Cok-kinos DV, Falk E, Fox KA, Julian D, Lengyel M, Neumann FJ, Ruzyllo W, Thygesen C, Underwood SR, Vahanian A, Verheugt FW, Wijns W, Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology: Management of acute myocardial infarction in patients pre-senting with ST-segment elevation. The Task Force on the Management of Acute Myocar-dial Infarction of the European Society of Cardiology. Eur Heart J 2003; 24:28-66.
20. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato JP, Pearle DL, Sloan MA, Smith SC Jr, American College of Cardiology, American Heart Association, Canadian Cardiovascular Society: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 2004; 44: 671-719.
21. Smith SC Jr, Dove JT, Jacobs AK, Kennedy JW, Kereiakes D, Kern MJ, Kuntz RE, Popma JJ, Schaff HV, Williams DO, Gibbons RJ, Alpert JP, Eagle KA, Faxon DP, Fuster V, Gardner TJ, Gregoratos G, Russell RO, Smith SC Jr, American College of Cardiology/ American Heart Association task force on practice guidelines (committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty), Society for Cardiac Angiography and Interventions: ACC/ AHA guidelines for percutaneous coronary intervention (revision of the 1993 PTCA guidelines)-executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee to revise the 1993 guidelines for percutaneous transluminal coronary angioplasty) endorsed by the Society for Cardiac Angiography and Interventions. Circulation 2001; 103: 3019-3041.
22. Silber S, Albertsson P, Aviles FF, Camici PG, Colombo A, Hamm C, Jorgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, Stone GW, Wijns W, Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology: Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology Eur Heart J 2005; 26: 804-847.
23. Kalarus Z, Lenarczyk R, Kowalczyk J, Ko-walski O, Gasior M, Was T, Zebik T, Krupa H, Chodór P, Polonski L, Zembala M: Im-portance of complete revascularization in patients with acute myocardial infarction treated with percutaneous coronary inter-vention. Am Heart J 2007; 153: 304-312. (Pubitemid 46096857)
24. Toprak O, Cirit M, Esi E, Postaci N, Yesil M, Bayata S: Hyperuricemia as a risk factor for contrast-induced nephropathy in patients with chronic kidney disease. Catheter Car-diovasc Interv 2006; 67:227-235. (Pubitemid 43235154)
25. Fang J, Alderman MH: Serum uric acid and cardiovascular mortality the NHANES I epidemiologic follow-up study, 1971-1992. Na-tional Health and Nutrition Examination Survey. JAMA 2000; 283: 2404-2410.
26. Meisinger C, Koenig W, Baumert J, Döring A: Uric acid levels are associated with all-cause and cardiovascular disease mortality independent of systemic inflammation in men from the general population: the MO-NICA/KORA cohort study. Arterioscler Thromb Vasc Biol 2008; 28:1186-1192.
27. Strasak A, Ruttmann E, Brant L, Kelleher C, Klenk J, Concin H, Diem G, Pfeiffer K, Ul-mer H, VHM&PP Study Group: Serum uric acid and risk of cardiovascular mortality: a prospective long-term study of 83,683 Aus-trian men. Clin Chem 2008; 54:273-284.
28. Strasak AM, Kelleher CC, Brant LJ, Rapp K, Ruttmann E, Concin H, Diem G, Pfeiffer KP, Ulmer H, VHM&PP Study Group: Serum uric acid is an independent predictor for all major forms of cardiovascular death in 28,613 elderly women: a prospective 21-year follow-up study. Int J Cardiol 2008; 125: 232-239.
29. Chambers DE, Parks DA, Patterson G, Roy R, McCord JM, Yoshida S, Parmley LF, Downey JM: Xanthine oxidase as a source of free radical damage in myocardial ischemia. J Mol Cell Cardiol 1985; 17:145-152.
30. Engberding N, Spiekermann S, Schaefer A, Heineke A, Wiencke A, Müller M, Fuchs M, Hilfiker-Kleiner D, Hornig B, Drexler H, Landmesser U: Allopurinol attenuates left ventricular remodeling and dysfunction af-ter experimental myocardial infarction: a new action for an old drug? Circulation 2004; 110:2175-2179.
31. Ekundayo OJ, Dell'italia LJ, Sanders PW, Ar-nett D, Aban I, Love TE, Filippatos G, Anker SD, Lloyd-Jones DM, Bakris G, Mujib M, Ahmed A: Association between hyperurice-mia and incident heart failure among older adults: A propensity-matched study. Int J Cardiol 2009; DOI: 10.1016/j.ijcard.2009. 01.010.
32. George J, Carr E, Davies J, Belch JJ, Struthers A: High dose allopurinol improves endothe-lial function by profoundly reducing vascu-lar oxidative stress and not by lowering uric acid. Circulation 2006; 114:2508-2516.
33. Chonchol M, Shlipak MG, Katz R, Sarnak MJ, Newman AB, Siscovick DS, Kestenbaum B, Carney JK, Fried LF: Relationship of uric acid with progression of kidney disease. Am J Kidney Dis 2007; 50: 239-247.
34. Siu YP, Leung KT, Tong MK, Kwan TH: Use of allopurinol in slowing the progression of renal disease through its ability to lower se-rum uric acid level. Am J Kidney Dis 2006; 47:51-59.
35. Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML: Uric acid stimu-lates vascular smooth muscle cell prolifera-tion and oxidative stress via the vascular re-nin-angiotensin system. J Hypertens 2008; 26: 269-275.
36. Mercuro G, Vitale C, Cerquetani E, Zoncu S, Deidda M, Fini M, Rosano GM: Effect of hyperuricemia upon endothelial function in patients at increased cardiovascular risk. Am J Cardiol 2004; 94: 932-935. (Pubitemid 39349561)
37. Kang DH, Park SK, Lee IK, Johnson RJ: Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 2005; 16: 3553-3562.
38. Sánchez-Lozada LG, Tapia E, Santamaría J, Avila-Casado C, Soto V, Nepomuceno T, Ro-dríguez-Iturbe B, Johnson RJ, Herrera-Acos-ta J: Mild hyperuricemia induces vasocon-striction and maintains glomerular Hypertension in normal and remnant kidney rats. Kidney Int 2005; 67: 237-247.
39. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, John-son RJ: A role for uric acid in the progression of renal disease. J Am Soc Nephrol 2002; 13: 2888-2897. (Pubitemid 35386908)
40. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K, Block ER, Prabhakar S, Johnson RJ: Hyperuricemia in-duces endothelial dysfunction. Kidney Int 2005; 67:1739-1742.
41. Sánchez-Lozada LG, Tapia E, López-Molina R, Nepomuceno T, Soto V, Avila-Casado C, Nakagawa T, Johnson RJ, Herrera-Acosta J, Franco M: Effects of acute and chronic L-ar-ginine treatment in experimental hyperuri-cemia. Am J Physiol Renal Physiol 2007; 292:F1238-F1244.
42. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL, Lan HY, Kivlighn S, Johnson RJ: Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 2001; 38:1101-1106.
43. Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD: Allopurinol improves endo-thelial dysfunction in chronic heart failure. Circulation 2002; 106:221-226.
44. Cingolani HE, Plastino JA, Escudero EM, Mangal B, Brown J, Pérez NG: The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study. J Card Fail 2006; 12:491-498.
45. Doehner W, Schoene N, Rauchhaus M, Ley-va-Leon F, Pavitt DV, Reaveley DA, Schuler G Coats AJ, Anker SD, Hambrecht R: Effects of xanthine oxidase inhibition with allopuri-nol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 place-bo-controlled studies. Circulation 2002; 105: 2619-2624.
46. Waring WS, Convery A, Mishra V, Shenkin A, Webb DJ, Maxwell SR: Uric acid reduces exercise-induced oxidative stress in healthy adults. Clin Sci 2003; 105:425-430.
47. Hare JM, Mangal B, Brown J, Fisher C Jr, Freudenberger R, Colucci WS, Mann DL, Liu P, Givertz MM, Schwarz RP, OPT-CHF In-vestigators: Impact of oxypurinol in patients with symptomatic heart failure. Results of the OPT-CHF study. J Am Coll Cardiol 2008; 51: 2301-2309.